Posted by Site Administrator on March 7, 2013
“In identifying the novel protein that abnormally accumulates in the brains of affected patients, we have uncovered a potentially new therapeutic target and biomarker that would allow clinicians to confirm diagnosis of the diseases,” says senior author Dr. Leonard Petrucelli, Chair of Neuroscience at Mayo Clinic in Florida.
Categories: ALS News, Research News, Treatments
| 
Tags: ALS, ALS community, ALS diagnosis, ALS diagnostics, ALS medical care, ALS research, ALS research funding, ALS treatments, amyotrophic lateral sclerosis, Bob Stehlin, C9ORF72, C9ORF72 gene, C9RANT, Dr. Leonard Petrucelli, Neuroscience at Mayo Clinic in Florida, PALS, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis
| 
No comments
Posted by Site Administrator on February 12, 2013
“This new finding sheds light on how the mutation causes these disorders, and it provides us with a marker that helps us track disease progression in patients with this disorder and potentially combat the disease,” says senior author Leonard Petrucelli, Ph.D., a molecular neuroscientist and director of the Department of Neuroscience at Mayo Clinic in Florida.
Categories: Research News, Technology, Treatments
| Tags: ALS community, ALS medical care, ALS research, ALS research funding, ALS treatments, amyotrophic lateral sclerosis, biomarker ALS, Bob Stehlin, C9ORF72 gene, C9RANT, Department of Neuroscience at Mayo Clinic Florida, DNA sequence ALS, frontotemporal dementia, Leonard Petrucelli, Lou Gehrig's disease, Mayo Clinic, motor neuron cells, Motor Neuron Disease, National Institutes of Health, neurodegenerative disorders, neuronal death and toxicity, PALS, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis
| No comments
